Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: Reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine

American Journal of Hematology

Volumn 82, Issue 9, 2007, Pages 792-797

  Richardson, Stephen K ^a   Newton, Sarah B ^a   Bach, Tami L ^a   Budgin, Jeanne B ^a   Benoit, Bernice M ^a   Lin, Julie H ^a   Yoon, Jessica S ^a   Wysocka, Maria ^a   Abrams, Charles S ^a   Rook, Alain H ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 2 Rhoads Pavilion ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR4; DIPEPTIDYL PEPTIDASE IV; RETINOID X RECEPTOR; THYMUS AND ACTIVATION REGULATED CHEMOKINE; ANTINEOPLASTIC AGENT; BETA CHEMOKINE; CC CHEMOKINE RECEPTOR 4; CCL17 PROTEIN, HUMAN; CHEMOKINE RECEPTOR; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SEZARY SYNDROME; T LYMPHOCYTE; AGED; CASE CONTROL STUDY; CELL CULTURE; COMPARATIVE STUDY; DRUG SCREENING; EVALUATION; FEMALE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; NEUTROPHIL CHEMOTAXIS; TIME;

AGED; ANTICARCINOGENIC AGENTS; CASE-CONTROL STUDIES; CELLS, CULTURED; CHEMOKINES, CC; CHEMOTAXIS, LEUKOCYTE; DRUG EVALUATION, PRECLINICAL; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RECEPTORS, CHEMOKINE; SEZARY SYNDROME; TETRAHYDRONAPHTHALENES; TIME FACTORS;

EID: 35748975688     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20952     Document Type: Article

References (21)

1. Wanderheid EC, Bernengo MG, Burg G, et al. Update on erythroderma cutaneous T-cell lymphoma: Report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002;46:95-106.
2. Ferenczi K, Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 2002;119:1405-1410.
3. Reiss Y, Proudfoot AE, Power CA, Campbell JJ, Butcher EC. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 2001;194:1541-1547.
4. Kakinuma T, Sugaya M, Nakamura K, et al. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: Serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 2003;48:23-30.
5. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994;76:301-314.
6. Picker LJ, Kishimoto TK, Smith CW, Warnock RA, Butcher EC. ELAM-1 is an adhesion molecule for skin-homing T cells. Nature 1991;349:796-799.
7. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997;389:978-981.
8. Campbell JJ, Haraldsen G, Pan J, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999;400:776-780.
9. Groves RW, Ross E, Barker JN, Ross JS, Camp RD, MacDonald DM. Effect of in vivo interleukin-1 on adhesion molecule expression in normal human skin. J Invest Dermatol 1992;98:384-387.
10. Sokolowska-Wojdylo M, Wenzel J, Gaffal E, et al. Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Br J Dermatol 2005;152:258-264.
11. Cheng SX, Kupper T. A new rexinoid for cutaneous T-cell lymphoma. Arch Dermatol 2001;137:649-652.
12. Budgin JB, Richardson SK, Newton SB, et al. Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol 2005;141:315-321.
13. Richardson SK, Lin JH, Vittorio CC, et al. High clinical response rate with multimodality immunomodulatory therapy for Sezary syndrome. Clin Lymphoma Myeloma 2006;7:226-232.
14. Richardson S, Budgin JB, Junkins-Hopkins JM, et al. Low-dose bexarotene and low-dose interferon α-2b for adult T-cell leukemia/lymphoma associated with human T-lymphotropic virus 1. Arch Dermatol 2005;141:301-304.
15. Introcaso CE, Hess SD, Kamoun M, Ubriani R, Gelfand JM, Rook AH. Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sezary syndrome. J Am Acad Dermatol 2005;53:428-434.
16. Bernengo MG, Novelli M, Quaglino P, et al. The relevance of the CD4+ CD26- subset in the identification of circulating Sezary cells. Br J Dermatol 2001;144:125-135.
17. Narducci MG, Scala E, Bresin A, et al. Skin homing of Sezary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood 2006;107:1108-1115.
18. Murphy G. Cutaneous T-cell lymphoma. Adv Pathol 1988;1:131-156.
19. Rook AH, Kubin M, Cassin M, et al. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol 1995;154:1491-1498.
20. Kim CH, Pelus LM, White JR, Broxmeyer HE. Differential chemotactic behavior of developing T cells in response to thymic chemokines. Blood 1998;91:4434-4443.
21. Sgonc R, Boeck G, Dietrich H, Gruber J, Recheis H, Wick G. Simultaneous determination of cell surface antigens and apoptosis. Trends Genet 1994;10:41-42.